Unicycive Q2 Loss Narrows to $0.06/Share; FDA Assigns OLC Facility Inspection, Cash Runway into 2027
UNCY sits 39% above its 52-week low of $3.71 on light trading volume (0.3× avg).
Summary
Unicycive reported a narrower Q2 net loss of $0.06 per share, aided by a non-cash warrant liability gain, and disclosed that the FDA has assigned a facility inspection for its OLC manufacturing vendor — a key step toward NDA resubmission.
Key Events · Earnings and Guidance · UNCY
-
Q2 Net Loss Narrows Sharply
Net loss was $(1.7)M, or $(0.06) per share, compared to $(6.5)M, or $(0.52) per share, in Q2 2025. The improvement was primarily due to an $8.0M non-cash gain from the change in fair value of warrant liability.
-
FDA Assigns OLC Facility Inspection
The FDA has assigned a facility inspection to the third-party manufacturing vendor for oxylanthanum carbonate (OLC). A successful inspection would enable the company to resubmit its NDA, which received a second CRL in June 2026 due to manufacturing deficiencies.
-
Cash Runway into 2027
Unaudited cash, cash equivalents, and marketable securities totaled $61.4 million as of June 30, 2026, providing expected runway into 2027. This follows $34.0M in ATM proceeds raised during the quarter.
-
Operating Expenses Rise on Commercial Prep
R&D expense increased to $2.8M from $1.8M, and G&A rose to $7.4M from $5.2M, driven by higher non-cash stock-based compensation and $0.4M in commercial launch preparation costs for OLC.
Analysis · UNCY · Life Sciences
Unicycive's second-quarter results delivered a sharply narrower net loss of $1.7 million, or $0.06 per share, versus a $6.5 million loss a year ago, largely thanks to a non-cash $8.0 million gain from the revaluation of warrant liabilities. The company ended the quarter with $61.4 million in cash and securities, providing runway into 2027. Critically, the FDA has assigned a facility inspection to the third-party manufacturer of its lead drug candidate, OLC, marking a concrete step toward resolving the manufacturing deficiencies that led to a second Complete Response Letter in June. A successful inspection would allow the company to resubmit its NDA, keeping the potential approval timeline alive. This filing combines a better-than-expected bottom line with a tangible regulatory catalyst, making it highly relevant for investors.
At the time of this filing, UNCY was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $3.71 to $8.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.